Trial Profile

A pharmacokinetics, pharmacodynamics, and tolerability of single- and multiple-dose of Janagliflozin in Chinese patients with Type-2 diabetes mellitus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Janagliflozin (Primary) ; Dapagliflozin
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

17 Jun 2019 New trial record
11 Jun 2019 Results assessing pharmacokinetics, pharmacodynamics, and tolerability of Janagliflozin presented at the 79th Annual Scientific Sessions of the American Diabetes Association
10 Jun 2019 Results published in the Sihuan Pharmaceutical Holdings Group Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com